Neoplasms

All Conditions

Blood and Lymph Conditions

Immune System Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Carcinoma

Lymphoma

Lymphoma, Follicular

Lymphoma, Large B-Cell, Diffuse

Sarcoma

Mesothelioma

Mesothelioma, Malignant

Lymphoma, B-Cell

Carcinoma, Medullary

Sarcoma, Synovial

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Neoplasms, Connective and Soft Tissue

Adenoma

Neoplasms, Glandular and Epithelial

Neoplasms, Mesothelial

Neoplasms, Connective Tissue

Carcinoma, Neuroendocrine

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Adenocarcinoma

Neoplasms, Nerve Tissue

Lymphosarcoma

Follicular Lymphoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Soft Tissue Sarcoma

Malignant Mesothelioma

Thyroid Cancer, Medullary

Renal Medullary Carcinoma

Synovial Sarcoma

Neuroendocrine Tumor

Neuroepithelioma

Amino Acids

All Drugs and Chemicals

Lysine

Participants will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol.

For participants on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.

Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.

Tazemetostat

Ipsen Medical Director

This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.

The aim of the study will be to assess the long-term safety of tezemetostat.

This open-label, multicenter, global study will provide continuing access to tazemetostat therapy for subjects who have completed their participation in a prior tazemetostat study (either with monotherapy or combination therapy)

without unacceptable toxicity, have not had evidence of tumor progression as defined by disease-appropriate standard criteria, and continue to receive clinical benefit from the therapy.

Subjects will receive tazemetostat as dictated in their antecedent study. Visits will be conducted per Standard of Care (SoC) as appropriate in each country and as determined by the Investigator. Subjects will be followed for long-term safety in addition to time to treatment failure (TTF) and overall survival (OS).

A Study to Assess the Long-term Safety of Tazemetostat

Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention Severity of adverse events experienced by all participants will be evaluated by the Investigator based on the CTCAE, version 5.0.

The average study drug exposure duration will be reported.

Defined as the interval of time between the date of the first dose of tazemetostat and the date of death due to any cause

Epizyme, Inc.

Spots Global Cancer Trial Database for epitheliod sarcoma (es)